Kommentar zu: „Efruxifermin bei metabolisch bedingter Steatohepatitis mit Leberzirrhose“

• Literatur

• 1 Sanyal A, Van Natta ML, Clark J. et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med 2021; 385: 1559-1569
• 2 Sanyal A, Harrison SA, Ratziu V. et al. The Natural History of Advanced Fibrosis due to Nonalcoholic Steatohepatitis: Data from the Simtuzumab Trials. Hepatology 2019; 70: 1913-1927
• 3 Harrison S, Bedossa P, Guy CD. et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med 2024; 390: 497-509
• 4 Sanyal A, Newsome PN, Kliers I. et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med 2025; 392: 2089-2099
• 5 Harrison SA, Wong VW, Okanoue T. et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol 2020; 73: 26-39